Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Down 12.0% in September

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totalling 4,600,000 shares, a decline of 12.0% from the September 15th total of 5,230,000 shares. Based on an average daily trading volume, of 389,800 shares, the days-to-cover ratio is currently 11.8 days. Currently, 18.6% of the company’s stock are sold short.

Institutional Trading of Arcturus Therapeutics

Large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in shares of Arcturus Therapeutics by 40.3% in the 4th quarter. Wellington Management Group LLP now owns 60,841 shares of the biotechnology company’s stock valued at $1,918,000 after buying an additional 17,491 shares during the period. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Arcturus Therapeutics by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 31,930 shares of the biotechnology company’s stock valued at $1,078,000 after buying an additional 778 shares during the period. Denali Advisors LLC acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at about $209,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Arcturus Therapeutics by 66.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,153 shares of the biotechnology company’s stock valued at $174,000 after buying an additional 2,064 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in shares of Arcturus Therapeutics by 148.0% in the 1st quarter. Principal Financial Group Inc. now owns 17,516 shares of the biotechnology company’s stock valued at $592,000 after buying an additional 10,454 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Performance

Arcturus Therapeutics stock opened at $20.97 on Wednesday. The business’s 50-day simple moving average is $21.02 and its two-hundred day simple moving average is $25.57. The company has a market cap of $564.76 million, a PE ratio of -5.36 and a beta of 2.61. Arcturus Therapeutics has a fifty-two week low of $17.52 and a fifty-two week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($1.85) by $1.21. The business had revenue of $49.86 million for the quarter, compared to the consensus estimate of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same quarter in the previous year, the business earned ($1.98) EPS. As a group, analysts predict that Arcturus Therapeutics will post -2.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ARCT. Leerink Partners began coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They set an “outperform” rating and a $70.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $71.40.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.